HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 288 filers reported holding HAEMONETICS CORP in Q4 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $77,273,499 | +0.5% | 862,620 | -4.4% | 0.04% | +4.8% |
| Q2 2023 | $76,859,624 | +3.3% | 902,744 | +0.4% | 0.04% | -6.7% |
| Q1 2023 | $74,378,017 | +85350.7% | 898,828 | -18.8% | 0.04% | -23.7% |
| Q4 2022 | $87,042 | -99.9% | 1,106,697 | -11.3% | 0.06% | -14.5% |
| Q3 2022 | $92,356,000 | +11.6% | 1,247,543 | -1.8% | 0.07% | +16.9% |
| Q2 2022 | $82,764,000 | +10.2% | 1,269,774 | +6.9% | 0.06% | +34.1% |
| Q1 2022 | $75,115,000 | +18.5% | 1,188,158 | -0.5% | 0.04% | +25.7% |
| Q4 2021 | $63,364,000 | -18.6% | 1,194,645 | +8.3% | 0.04% | -27.1% |
| Q3 2021 | $77,853,000 | +6.3% | 1,102,893 | +0.4% | 0.05% | +4.3% |
| Q2 2021 | $73,220,000 | +332.2% | 1,098,733 | +619.9% | 0.05% | +283.3% |
| Q1 2021 | $16,943,000 | -7.4% | 152,627 | -1.0% | 0.01% | -14.3% |
| Q4 2020 | $18,303,000 | +35.6% | 154,134 | -0.4% | 0.01% | +16.7% |
| Q3 2020 | $13,499,000 | -10.8% | 154,714 | -8.4% | 0.01% | -20.0% |
| Q2 2020 | $15,129,000 | -14.2% | 168,921 | -4.5% | 0.02% | -31.8% |
| Q1 2020 | $17,625,000 | -18.8% | 176,847 | -6.4% | 0.02% | 0.0% |
| Q4 2019 | $21,713,000 | -27.6% | 188,971 | -20.5% | 0.02% | -33.3% |
| Q3 2019 | $29,995,000 | +5.9% | 237,788 | +1.1% | 0.03% | +6.5% |
| Q2 2019 | $28,317,000 | -41.1% | 235,306 | -54.2% | 0.03% | +3.3% |
| Q1 2019 | $48,043,000 | +97.8% | 514,303 | +111.9% | 0.03% | -9.1% |
| Q4 2018 | $24,285,000 | +64.8% | 242,724 | +88.7% | 0.03% | +83.3% |
| Q3 2018 | $14,740,000 | -20.1% | 128,646 | -37.5% | 0.02% | -25.0% |
| Q2 2018 | $18,453,000 | +15.1% | 205,764 | -6.1% | 0.02% | +14.3% |
| Q1 2018 | $16,030,000 | +22.3% | 219,111 | -2.9% | 0.02% | +23.5% |
| Q4 2017 | $13,105,000 | +20.1% | 225,639 | -7.2% | 0.02% | +13.3% |
| Q3 2017 | $10,916,000 | +14.4% | 243,275 | +0.7% | 0.02% | +7.1% |
| Q2 2017 | $9,539,000 | -2.8% | 241,547 | -0.2% | 0.01% | -12.5% |
| Q1 2017 | $9,817,000 | -8.8% | 241,967 | -9.6% | 0.02% | -15.8% |
| Q4 2016 | $10,760,000 | +11.0% | 267,667 | -0.0% | 0.02% | +11.8% |
| Q3 2016 | $9,694,000 | +23.8% | 267,712 | +4.0% | 0.02% | +13.3% |
| Q2 2016 | $7,832,000 | +4.5% | 257,467 | +17.5% | 0.02% | +7.1% |
| Q1 2016 | $7,494,000 | +6.1% | 219,127 | +0.0% | 0.01% | 0.0% |
| Q4 2015 | $7,064,000 | +4.6% | 219,110 | +4.9% | 0.01% | 0.0% |
| Q3 2015 | $6,752,000 | -13.9% | 208,920 | +10.2% | 0.01% | -6.7% |
| Q2 2015 | $7,839,000 | -10.2% | 189,520 | -2.4% | 0.02% | -11.8% |
| Q1 2015 | $8,725,000 | +20.0% | 194,245 | 0.0% | 0.02% | +13.3% |
| Q4 2014 | $7,269,000 | +17.2% | 194,245 | +9.3% | 0.02% | +15.4% |
| Q3 2014 | $6,203,000 | -1.0% | 177,645 | 0.0% | 0.01% | 0.0% |
| Q2 2014 | $6,267,000 | +30.4% | 177,645 | +20.5% | 0.01% | +18.2% |
| Q1 2014 | $4,805,000 | -22.9% | 147,445 | -0.4% | 0.01% | -21.4% |
| Q4 2013 | $6,235,000 | -7.6% | 147,995 | -12.6% | 0.01% | -17.6% |
| Q3 2013 | $6,749,000 | -3.6% | 169,245 | 0.0% | 0.02% | -5.6% |
| Q2 2013 | $6,998,000 | – | 169,245 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |